45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
12,831
Insurances with rates
9
CPT / HCPCS codes
11,741
Source MRF
Most expensive procedures (gross)
J9228
$85,101
IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION
Gross
$211,865
J9228
$85,101
IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION
Gross
$211,865
J2350
$46,255
OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION
Gross
$115,156
J2350
$46,255
OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION
Gross
$115,156
J0638
$44,511
CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION
Gross
$110,813
J0638
$44,511
CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION
Gross
$110,813
J9309
$41,348
POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION
Gross
$102,938
J9309
$41,348
POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION
Gross
$102,938
J3357
$32,179
USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE
Gross
$80,111
J3357
$32,179
USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE
Gross
$80,111
33270
$27,442
HC INS/REP SUBC DEFIBRILLATOR
Gross
$68,318
33270
$27,442
HC INS/REP SUBC DEFIBRILLATOR
Gross
$68,318
J9042
$26,759
BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION
Gross
$66,619
J9042
$26,759
BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION
Gross
$66,619
J9022
$26,153
ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION
Gross
$65,111
J9022
$26,153
ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION
Gross
$65,111
J9119
$25,522
CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION
Gross
$63,539
J9119
$25,522
CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION
Gross
$63,539
J1930
$24,910
LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE
Gross
$62,016
J1930
$24,910
LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE
Gross
$62,016
33289
$23,293
HC TCAT IMPL WRLS P-ART PRS SNR
Gross
$57,990
33289
$23,293
HC TCAT IMPL WRLS P-ART PRS SNR
Gross
$57,990
C2642
$23,225
GAMMATILE THERAPY 11PK GT-11
Gross
$57,820
C2642
$23,225
GAMMATILE THERAPY 11PK GT-11
Gross
$57,820
J9144
$23,072
DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN
Gross
$57,439
J9144
$23,072
DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN
Gross
$57,439
33264
$22,527
HC REMOVAL&REPL ICD GN MULT LD
Gross
$56,082
33264
$22,527
HC REMOVAL&REPL ICD GN MULT LD
Gross
$56,082
J9037
$22,329
BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION
Gross
$55,590
J9037
$22,329
BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION
Gross
$55,590
J2997
$21,001
ALTEPLASE 100 MG INTRAVENOUS SOLUTION
Gross
$52,285
J2997
$21,001
ALTEPLASE 100 MG INTRAVENOUS SOLUTION
Gross
$52,285
J3380
$20,118
VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION
Gross
$50,085
J3380
$20,118
VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION
Gross
$50,085
0795T
$19,223
TCAT INS 2CHMBR LDLS PM CMPL
Gross
$47,856
0795T
$19,223
TCAT INS 2CHMBR LDLS PM CMPL
Gross
$47,856
0796T
$19,223
TCAT INS 2CHMBR LDLS PM RA
Gross
$47,856
0796T
$19,223
TCAT INS 2CHMBR LDLS PM RA
Gross
$47,856
0797T
$19,223
TCAT INS 2CHMBR LDLS PM RV
Gross
$47,856
0797T
$19,223
TCAT INS 2CHMBR LDLS PM RV
Gross
$47,856
0801T
$19,223
TCAT RMV&RPL 2CHMBR LDLS PM
Gross
$47,856
0801T
$19,223
TCAT RMV&RPL 2CHMBR LDLS PM
Gross
$47,856
0802T
$19,223
TCAT RMV&RPL2CHMB LDLS PM RA
Gross
$47,856
0802T
$19,223
TCAT RMV&RPL2CHMB LDLS PM RA
Gross
$47,856
0803T
$19,223
TCAT RMV&RPL2CHMB LDLS PM RV
Gross
$47,856
0803T
$19,223
TCAT RMV&RPL2CHMB LDLS PM RV
Gross
$47,856
J9223
$19,182
LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION
Gross
$47,756
J9223
$19,182
LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION
Gross
$47,756
J9301
$19,049
OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION
Gross
$47,423
J9301
$19,049
OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION
Gross
$47,423
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $85,101 | $88,983 | $192,797 | 6 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $85,101 | $180 | $192,797 | 23 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $46,255 | $48,366 | $104,792 | 6 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $46,255 | $58.66 | $104,792 | 23 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $44,511 | $46,541 | $100,840 | 6 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $44,511 | $139 | $100,840 | 23 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $41,348 | $43,234 | $93,674 | 6 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $41,348 | $134 | $93,674 | 23 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $32,179 | $33,647 | $72,901 | 6 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $32,179 | $155 | $72,901 | 23 |
| 33270 | HC INS/REP SUBC DEFIBRILLATOR | $68,318 | $27,442 | $62,169 | $62,169 | 1 |
| 33270 | HC INS/REP SUBC DEFIBRILLATOR | $68,318 | $27,442 | $5,386 | $63,000 | 22 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $26,759 | $27,980 | $60,623 | 6 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $26,759 | $254 | $60,623 | 23 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $26,153 | $27,346 | $59,251 | 6 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $26,153 | $89.43 | $59,251 | 23 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $25,522 | $26,686 | $57,820 | 6 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $25,522 | $28.19 | $57,820 | 23 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $62,016 | $24,910 | $26,047 | $56,434 | 6 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $62,016 | $24,910 | $36.01 | $56,434 | 23 |
| 33289 | HC TCAT IMPL WRLS P-ART PRS SNR | $57,990 | $23,293 | $52,771 | $52,771 | 1 |
| 33289 | HC TCAT IMPL WRLS P-ART PRS SNR | $57,990 | $23,293 | $5,386 | $55,861 | 22 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $23,225 | $23,128 | $52,616 | 6 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $23,225 | $106 | $52,616 | 22 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $23,072 | $24,125 | $52,270 | 6 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $23,072 | $53.71 | $52,270 | 23 |
| 33264 | HC REMOVAL&REPL ICD GN MULT LD | $56,082 | $22,527 | $51,035 | $51,035 | 1 |
| 33264 | HC REMOVAL&REPL ICD GN MULT LD | $56,082 | $22,527 | $5,386 | $63,000 | 22 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $22,329 | $23,348 | $50,587 | 6 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $22,329 | $13,586 | $50,587 | 14 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $21,001 | $21,960 | $47,579 | 6 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $21,001 | $92.5 | $47,579 | 23 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $20,118 | $21,036 | $45,577 | 6 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $20,118 | $21.68 | $45,577 | 23 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $47,856 | $19,223 | $43,549 | $43,549 | 1 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $47,856 | $19,223 | $11,696 | $43,549 | 14 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $47,856 | $19,223 | $43,549 | $43,549 | 1 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $47,856 | $19,223 | $11,696 | $43,549 | 14 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $47,856 | $19,223 | $43,549 | $43,549 | 1 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $47,856 | $19,223 | $11,696 | $43,549 | 14 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $47,856 | $19,223 | $43,549 | $43,549 | 1 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $47,856 | $19,223 | $11,696 | $43,549 | 14 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $47,856 | $19,223 | $43,549 | $43,549 | 1 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $47,856 | $19,223 | $11,696 | $43,549 | 14 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $47,856 | $19,223 | $43,549 | $43,549 | 1 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $47,856 | $19,223 | $11,696 | $43,549 | 14 |
| J9223 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $47,756 | $19,182 | $20,057 | $43,458 | 6 |
| J9223 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $47,756 | $19,182 | $203 | $43,458 | 23 |
| J9301 | OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION | $47,423 | $19,049 | $19,918 | $43,155 | 6 |
| J9301 | OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION | $47,423 | $19,049 | $77.09 | $43,155 | 23 |
Showing top 50 of 12,831 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.